{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II+Clinical+Trial&page=2", "query": { "condition": "Phase II Clinical Trial", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II+Clinical+Trial&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T07:36:20.088Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07003295", "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-08-14", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 7, "location_summary": "Duarte, California • Atlanta, Georgia • Columbus, Ohio + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07003295" }, { "nct_id": "NCT01511081", "title": "Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small-cell Lung Cancer" ], "interventions": [ { "name": "SBRT (stereotactic body radiotherapy)", "type": "RADIATION" }, { "name": "SBPT (stereotactic body proton therapy)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-08", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-12-07", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01511081" }, { "nct_id": "NCT06843811", "title": "Sirolimus for Leigh Syndrome", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leigh Syndrome" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Demczko", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "6 Months to 55 Years" }, "enrollment_count": 15, "start_date": "2025-02-27", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843811" }, { "nct_id": "NCT00612664", "title": "Phase II, 2nd Line Melanoma - RAND Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Anti-CD137 (4-1BB) (BMS-663513)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2008-03", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612664" }, { "nct_id": "NCT00362570", "title": "Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oligoastrocytoma, Mixed", "Anaplastic Oligodendroglioma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2005-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362570" }, { "nct_id": "NCT00225173", "title": "Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2001-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-08-27", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225173" }, { "nct_id": "NCT02921269", "title": "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Recurrent Cervical Carcinoma", "Stage IV Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVB Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2017-03-10", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 22, "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921269" }, { "nct_id": "NCT04736173", "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Nonsquamous Non Small Cell Lung Cancer", "Squamous Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2021-02-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 3, "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Kingwood", "state": "Texas" }, { "city": "Blacksburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736173" }, { "nct_id": "NCT02425683", "title": "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-03-26", "completion_date": "2017-09-21", "has_results": false, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Including Dallas, TX, Ocala, FL, Denver, CO, Florida", "locations": [ { "city": "Including Dallas, TX, Ocala, FL, Denver, CO", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02425683" }, { "nct_id": "NCT00468169", "title": "Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Twice-daily radiation", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Accelerated fraction radiotherapy with concomitant boost", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2006-07", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-06-26T07:36:20.088Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00468169" } ] }